Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

Ariyawutyakorn, Witthawat; Saichaemchan, Siriwimon; Varella-Garcia, Marileila

doi:10.7150/jca.12663

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2016; 7(6):633-649. doi:10.7150/jca.12663 This issue Cite

Review

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

Witthawat Ariyawutyakorn^1,3, Siriwimon Saichaemchan^2,3, Marileila Varella-Garcia^3✉

1. Faculty of Medicine, Chiang Mai University, 110 Intavarorod Rd., Muang, Chiang Mai, Thailand 50200.
2. Division of Oncology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, 315 Phayathai Rd., Ratchathewi, Bangkok, Thailand 10400.
3. Department of Medicine, University of Colorado, Anschutz Medical Campus, 12801 East 17^th Ave, RC1 South, L18-8118, Mail Stop 8117, Aurora, Colorado, USA 80045.

Citation:

Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. J Cancer 2016; 7(6):633-649. doi:10.7150/jca.12663. https://www.jcancer.org/v07p0633.htm

Other styles

Abstract

The MET signaling pathway plays an important role in normal physiology and its deregulation has proved critical for development of numerous solid tumors. Different technologies have been used to investigate the genomic and proteomic status of MET in cancer patients and its association with disease prognosis. Moreover, with the development of targeted therapeutic drugs, there is an urgent need to identify potential biomarkers for selection of patients who are more likely to derive benefit from these agents. Unfortunately, the variety of technical platforms and analysis criteria for diagnosis has brought confusion to the field and a lack of agreement in the evaluation of MET status as a prognostic or predictive marker for targeted therapy agents. We review the molecular mechanisms involved in the deregulation of the MET signaling pathway in solid tumors, the different technologies used for diagnosis, and the main factors that affect the outcome, emphasizing the urge for completing analytical and clinical validation of these tests. We also review the current clinical studies with MET targeted agents, which mostly focus on lung cancer.

Keywords: MET, HGF, FISH, IHC, molecular testing, targeted therapy.

Citation styles

APA

Ariyawutyakorn, W., Saichaemchan, S., Varella-Garcia, M. (2016). Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. Journal of Cancer, 7(6), 633-649. https://doi.org/10.7150/jca.12663.

ACS

Ariyawutyakorn, W.; Saichaemchan, S.; Varella-Garcia, M. Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. J. Cancer 2016, 7 (6), 633-649. DOI: 10.7150/jca.12663.

NLM

CSE

Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. 2016. Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. J Cancer. 7(6):633-649.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.